Open-Access Science for Better Cancer Drugs
Dr. David Kerr says 90% of new cancer drugs ' fail. ' To reverse this rate, he advocates a novel model for drug development in which science is shared in open-access, industry-academic partnerships.
Source: Medscape Pathology and Laboratory Medicine Podcast - Category: Laboratory Medicine Authors: Medscape Source Type: podcasts
More News: Academia | Cancer | Cancer & Oncology | Laboratory Medicine | Partnerships | Pathology | Podcasts | Science